Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity

The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

30 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Mahmoud Younis

Cairo, 11759, Egypt

About this study

The aim was to show if a combination of topiramate and empagliflozin have the greatest weight decreasing effect in comparison to each drug alone and to group with no treatment( control group).

Materials and methods 200 obese patients 4 groups. had been monitored in a private clinic, each group 50 patients number, with 35 females and 15 males who were already on treatment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

stable weight in the previous 6 months.
a sedentary lifestyle.
no history of diabetes mellitus.
taking medication that affects appetite, or weight within the past 6 months

Exclusion criteria

severe anemia
hypothyroidism and hyperthyroidism
Diabetes mellitus
moderate to severe liver or kidney disease
body mass index less than 30

Treatment and study plan

The intervention being studied

Drug

Intervention Other Names have not been specified

Other names: "empagliflozine", "jardiance®"), "topiramate", "conviban®"

Primary outcomes

change in weight

Time frame: 6 months

weight measurement

Sponsors and collaborators

Lead sponsor

Ministry of Health and Population, Egypt

Other Gov

Registry information

Official study title

Combination of Topiramate(Conviban) and Empagliflozin(Jardiance) is Considered a Good Option for the Treatment of Obesity

Important dates

Study start: 2019
Primary completion: 2019
Study completion: 2019
First posted: Aug 2, 2019
Registry last updated: Aug 2, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed